COVID-19 is a global pandemic impacting the daily living of millions. As variants of the virus evolve, a complete comprehension of the disease and drug targets becomes a decisive duty. The Omicron variant, for example, has a notably high transmission rate verified in 155 countries. We performed integrative transcriptomic and network analyses to identify drug targets and diagnostic biomarkers and repurpose FDA-approved drugs for SARS-CoV-2. Upon the enrichment of 464 differentially expressed genes, pathways regulating the host cell cycle were significant. Regulatory and interaction networks featured hsa-mir-93-5p and hsa-mir-17-5p as blood biomarkers while hsa-mir-15b-5p as an antiviral agent. MYB, RRM2, ERG, CENPF, CIT, and TOP2A are potential drug targets for treatment. HMOX1 is suggested as a prognostic biomarker. Enhancing HMOX1 expression by neem plant extract might be a therapeutic alternative. We constructed a drug-gene network for FDA-approved drugs to be repurposed against the infection. The key drugs retrieved were members of anthracyclines, mitotic inhibitors, anti-tumor antibiotics, and CDK1 inhibitors. Additionally, hydroxyquinone and digitoxin are potent TOP2A inhibitors. Hydroxyurea, cytarabine, gemcitabine, sotalol, and amiodarone can also be redirected against COVID-19. The analysis enforced the repositioning of fluorouracil and doxorubicin, especially that they have multiple drug targets, hence less probability of resistance.

BackgroundIn many pregnant women, it is very difficult to accurately assess the fetal gestation age, due to pregnancy on top of lactation or contraceptive method, unsure of date, irregular cycles, late booking and missing the dating scan. Therefore, we might have a wrong diagnosis of preterm or postterm pregnancy, which will affect the outcome of pregnancy. Patients and methods:In our prospective study, we examined 70 normal pregnant women and 70 intrauterine growth restricted (IUGR) pregnancy cases after Ethical Committee approval and informed written consent, to assess the effectivity of transcerebellar diameter (TCD) in detection the age of gestation in normal pregnancy and IUGR cases in relation to other ultrasound parameters as biparietal diameter (BPD), head circumference (HC), femur length (FL), abdominal circumference (AC). In addition, TCD/AC ratio was assessed for its efficiency in diagnosing IUGR pregnancy if its value was above 95 th percentile. Results: Our results showed no significant difference between the mean gestation age detected by TCD compared to the actual mean gestation age in normal as well as IUGR cases, in addition the TCD showed the highest diagnostic accuracy of 95% in detection of gestation age in IUGR within 2 weeks. TCD/AC ratio showed accuracy of 91.43% in diagnosis of IUGR if ratio above 95 Th percentile. Conclusion: TCD is a very important parameter in diagnosis of IUGR cases and proper assessment of gestation age.